Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Other Operating Expenses history runs 17 years deep, the most recent figure standing at $122.8 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $122.8 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 139.66% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 94.44% from the prior year.
• Other Operating Expenses eased to $122.8 million in Q1 2026 per JAZZ's latest filing, from $323.3 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.2 billion in Q2 2025 and bottomed at $122.8 million in Q1 2026.
• The 5-year median for Other Operating Expenses is $283.4 million (2022), against an average of $364.6 million.
• Across the five-year window, Other Operating Expenses sank 59.28% in 2023 and surged 346.48% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $679.8 million in 2022, then sank by 59.28% to $276.8 million in 2023, then rose by 3.91% to $287.6 million in 2024, then gained by 12.4% to $323.3 million in 2025, then slumped by 62.01% to $122.8 million in 2026.
• Per Business Quant, the three latest JAZZ Other Operating Expenses figures stand at $122.8 million (Q1 2026), $323.3 million (Q4 2025), and $339.7 million (Q3 2025).